Published in Oncoimmunology on November 01, 2012
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res (2014) 2.03
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clin Cancer Res (2015) 1.27
Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. J Immunother Cancer (2013) 0.96
Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol (2015) 0.96
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. Oncoimmunology (2014) 0.90
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity (2016) 0.89
Clonal evolution of glioblastoma under therapy. Nat Genet (2016) 0.85
A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer. PLoS One (2016) 0.78
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology (2016) 0.75
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A (2005) 2.93
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 2.63
Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol (1996) 2.11
Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood (2012) 1.65
MHC class I/peptide stability: implications for immunodominance, in vitro proliferation, and diversity of responding CTL. J Immunol (1998) 1.51
Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. J Natl Cancer Inst (1995) 1.47
Prediction of epitopes using neural network based methods. J Immunol Methods (2010) 1.35
Lessons from applied ecology: cancer control using an evolutionary double bind. Cancer Res (2009) 1.23
Autoimmunity associated with immunotherapy of cancer. Blood (2011) 1.22
Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol (2001) 1.18
Machine learning competition in immunology - Prediction of HLA class I binding peptides. J Immunol Methods (2011) 1.18
Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet (1995) 1.17
A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res (2001) 1.15
A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol (1999) 1.06
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother (2008) 1.00
Comparative immunopeptidomics of humans and their pathogens. Proc Natl Acad Sci U S A (2004) 0.99
Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer (1996) 0.95
State of the art and challenges in sequence based T-cell epitope prediction. Immunome Res (2010) 0.95
Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res (2008) 0.95
A census of predicted mutational epitopes suitable for immunologic cancer control. Hum Immunol (2010) 0.89
An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. Lung Cancer (2007) 0.87
Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. Br J Cancer (1996) 0.87
Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J Immunol (2003) 0.85
Oncogene products represent potential targets of tumor vaccines. Cancer Immunol Immunother (1996) 0.76
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat (2009) 7.91
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet (2006) 7.16
Reliability and reproducibility issues in DNA microarray measurements. Trends Genet (2005) 6.79
Robustness of cellular functions. Cell (2004) 6.65
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. Nucleic Acids Res (2004) 4.43
Chromosomal instability confers intrinsic multidrug resistance. Cancer Res (2011) 3.70
Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements. BMC Bioinformatics (2005) 3.66
A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc Natl Acad Sci U S A (2008) 3.57
Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med (2010) 2.62
Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A (2009) 2.12
Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics (2011) 2.09
Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res (2011) 2.05
Increased measurement accuracy for sequence-verified microarray probes. Physiol Genomics (2004) 1.75
Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS One (2009) 1.55
Replacing cRNA targets with cDNA reduces microarray cross-hybridization. Nat Biotechnol (2006) 1.49
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42
Parallel evolution of tumour subclones mimics diversity between tumours. J Pathol (2013) 1.42
Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.38
Correction of technical bias in clinical microarray data improves concordance with known biological information. Genome Biol (2008) 1.27
Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. J Cell Biochem (2010) 1.25
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med (2010) 1.12
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One (2013) 1.11
Prognostic and predictive markers in metastatic renal cell carcinoma. J Clin Oncol (2013) 1.08
Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status. PLoS One (2010) 0.97
Optimization of the BLASTN substitution matrix for prediction of non-specific DNA microarray hybridization. Nucleic Acids Res (2009) 0.92
Deconvoluting complex tissues for expression quantitative trait locus-based analyses. Philos Trans R Soc Lond B Biol Sci (2013) 0.87
Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Cancer Res (2004) 0.85
Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. Breast Cancer Res (2008) 0.83
CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J Pathol (2011) 0.83
Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response. BMC Bioinformatics (2011) 0.81
Biasogram: visualization of confounding technical bias in gene expression data. PLoS One (2013) 0.81
Concordance of exon array and real-time PCR assessment of gene expression following cancer cell cytotoxic drug exposure. Cell Cycle (2008) 0.78
A survey of methods for classification of gene expression data using evolutionary algorithms. Expert Rev Mol Diagn (2006) 0.77
A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. Oncotarget (2011) 0.76
Trading "wet-work" for network. Nat Biotechnol (2002) 0.75
Assessing the significance of consistently mis-regulated genes in cancer associated gene expression matrices. Bioinformatics (2002) 0.75
Build your own (virtual) cell. Trends Pharmacol Sci (2002) 0.75